News & Updates

The modified-release formulation of novel oral phosphodiesterase-4 (PDE4) inhibitor orismilast shows therapeutic potential in adults with moderate-to-severe psoriasis, with high rates of clinical response as compared with placebo, according to data from the phase IIb IASOS trial presented at AAD 2023.

Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.

Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.

A free online telepharmacy service, developed in the Philippines during the COVID-19 pandemic, may be used to provide and simplify medication information as part of primary care, reports a study.

Anticoagulation therapy with apixaban yields lower rates of ischaemic stroke and intracranial and extracranial major bleeding compared with other oral anticoagulants (OACs) in patients with atrial fibrillation (AF), with the magnitude of benefit for major bleeding even greater for those who have dementia, according to a study.